Nodular lymphocyte-predominant Hodgkin lymphoma

Semin Hematol. 2016 Jul;53(3):190-202. doi: 10.1053/j.seminhematol.2016.05.009. Epub 2016 May 13.

Abstract

Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare subtype of Hodgkin lymphoma with distinct clinicopathologic features. It is typified by the presence of lymphocyte predominant (LP) cells, which are CD20(+) but CD15(-) and CD30(-) and are found scattered amongst small B lymphocytes arranged in a nodular pattern. Despite frequent and often late or multiple relapses, the prognosis of NLPHL is very favorable. There is an inherent risk of secondary aggressive non-Hodgkin lymphoma (NHL) and studies support that risk is highest in those with splenic involvement at presentation. Given disease rarity, the optimal management is unclear and opinions differ as to whether treatment paradigms should be similar to or differ from those for classical Hodgkin lymphoma (CHL). This review provides an overview of the existing literature describing pathological subtypes, outcome and treatment approaches for NLPHL.

Keywords: Nodular lymphocyte-predominant Hodgkin lymphoma; Pathology; Treatment.

Publication types

  • Review

MeSH terms

  • Adult
  • B-Lymphocytes / pathology
  • Hodgkin Disease / diagnosis*
  • Hodgkin Disease / pathology
  • Humans
  • Lymphoma, Non-Hodgkin / diagnosis
  • Male
  • Prognosis